EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 2%

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) were up 2% during trading on Tuesday . The stock traded as high as $21.72 and last traded at $21.71. Approximately 27,523 shares changed hands during trading, a decline of 97% from the average daily volume of 944,644 shares. The stock had previously closed at $21.28.

Analysts Set New Price Targets

Several analysts recently commented on EYPT shares. JPMorgan Chase & Co. started coverage on shares of EyePoint Pharmaceuticals in a research report on Monday, January 22nd. They set an “overweight” rating and a $35.00 price objective on the stock. Capital One Financial reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Mizuho raised their price target on shares of EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, HC Wainwright dropped their price target on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, January 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $33.86.

EyePoint Pharmaceuticals Stock Up 1.8 %

The company’s 50 day moving average price is $24.45 and its two-hundred day moving average price is $18.15.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The firm had revenue of $14.03 million for the quarter, compared to analysts’ expectations of $8.71 million. During the same quarter in the prior year, the business earned ($0.61) EPS. On average, research analysts expect that EyePoint Pharmaceuticals, Inc. will post -1.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 49,325 shares of the firm’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $25.66, for a total transaction of $1,265,679.50. Following the sale, the insider now owns 36,505 shares in the company, valued at approximately $936,718.30. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other EyePoint Pharmaceuticals news, insider Dario A. Paggiarino sold 5,135 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.00, for a total transaction of $128,375.00. Following the sale, the insider now owns 36,505 shares in the company, valued at approximately $912,625. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dario A. Paggiarino sold 49,325 shares of the stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $25.66, for a total transaction of $1,265,679.50. Following the sale, the insider now directly owns 36,505 shares of the company’s stock, valued at $936,718.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,169 shares of company stock worth $1,437,509. Company insiders own 13.05% of the company’s stock.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in EyePoint Pharmaceuticals by 103.4% during the 3rd quarter. Barclays PLC now owns 45,659 shares of the company’s stock valued at $365,000 after buying an additional 23,208 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of EyePoint Pharmaceuticals in the third quarter valued at $574,000. Scotia Capital Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 144.9% in the third quarter. Scotia Capital Inc. now owns 90,963 shares of the company’s stock valued at $727,000 after purchasing an additional 53,820 shares in the last quarter. Jump Financial LLC grew its holdings in shares of EyePoint Pharmaceuticals by 318.5% in the third quarter. Jump Financial LLC now owns 48,968 shares of the company’s stock valued at $391,000 after purchasing an additional 37,268 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of EyePoint Pharmaceuticals by 487.6% in the third quarter. UBS Group AG now owns 526,848 shares of the company’s stock valued at $4,210,000 after purchasing an additional 437,190 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.